Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review

Drug Resistance Updates

Volumn 14, Issue 3, 2011, Pages 177-190

  Murphy, Mark ^a   Stordal, Britta ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Cisplatin; Erlotinib; Gefitinib; NSCLC; Ovarian cancer; Platinum

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; ROFECOXIB; TAMOXIFEN;

CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CROSS RESISTANCE; DRUG CHOICE; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; GENE DOSAGE; GENE MUTATION; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; UTERINE TUBE TUMOR;

EID: 79958227079     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2011.02.004     Document Type: Article

References (121)

1. S. Akiyama, A. Fojo, J.A. Hanover, I. Pastan, and M.M. Gottesman Isolation and genetic characterization of human KB cell lines resistant to multiple drugs Somat. Cell Mol. Genet. 11 1985 117 126 (Pubitemid 15149285)
2. C.M. Annunziata, A.J. Walker, L. Minasian, M. Yu, H. Kotz, and B.J. Wood Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2 Clin. Cancer Res. 16 2010 664 672
3. H. Arias-Pulido, N. Joste, A. Chavez, C.Y. Muller, D. Dai, and H.O. Smith Absence of epidermal growth factor receptor mutations in cervical cancer Int. J. Gynecol. Cancer 18 2008 749 754 (Pubitemid 352020185)
4. H. Bai, L. Mao, H.S. Wang, J. Zhao, L. Yang, and T.T. An Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer J. Clin. Oncol. 7 2009 2653 2659
5. M.N. Balak, Y. Gong, G.J. Riely, R. Somwar, A.R. Li, and M.F. Zakowski Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors Clin. Cancer Res. 12 2006 6494 6501 (Pubitemid 44799723)
6. S. Bamford, E. Dawson, S. Forbes, J. Clements, R. Pettett, and A. Dogan The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website Br. J. Cancer 91 2004 355 358 (Pubitemid 39037083)
7. D.W. Bell, T.J. Lynch, S.M. Haserlat, P.L. Harris, R.A. Okimoto, and B.W. Brannigan Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials J. Clin. Oncol. 23 2005 8081 8092 (Pubitemid 46657411)
8. V. Benedetti, P. Perego, B.G. Luca, E. Corna, S. Tinelli, and S.C. Righetti Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds Mol. Cancer Ther. 7 2008 679 687 (Pubitemid 351482150)
9. J.J. Biagi, A.M. Oza, H.I. Chalchal, R. Grimshaw, S.L. Ellard, and U. Lee A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study Ann. Oncol. 2010 10.1093/annonc/mdq357
10. R. Bianco, I. Shin, C.A. Ritter, F.M. Yakes, A. Basso, and N. Rosen Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene 22 2003 2812 2822 (Pubitemid 36609595)
11. G.R. Blumenschein Jr., U. Gatzemeier, F. Fossella, D.J. Stewart, L. Cupit, and F. Cihon Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer J. Clin. Oncol. 27 2009 4274 4280
12. P. Borst, S. Rottenberg, and J. Jonkers How do real tumors become resistant to cisplatin? Cell Cycle 7 2008 1353 1359 (Pubitemid 351872573)
13. V. Brabec, and J. Kasparkova Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs Drug Resist. Updat. 8 2005 131 146 (Pubitemid 41267064)
14. S.K. Chambers, M.C. Clouser, A.F. Baker, D.J. Roe, H. Cui, and M.A. Brewer Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer Clin. Cancer Res. 16 2010 5320 5328
15. Y.M. Chen, J.M. Liu, T.Y. Chou, R.P. Perng, C.M. Tsai, and J. Whang-Peng Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy Cancer 109 2007 1821 1828 (Pubitemid 46668546)
16. T.M. Chin, M.P. Quinlan, A. Singh, L.V. Sequist, T.J. Lynch, and D.A. Haber Reduced erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment Clin. Cancer Res. 14 2008 6867 6876
17. City of Hope Molecular Diagnostic Laboratory EGFR Mutation Statistics in NSCLC 2010
18. M. Clynes, A. Redmond, E. Moran, and U. Gilvarry Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A Cytotechnology 10 1992 75 89
19. Q. Dai, Y.H. Ling, M. Lia, Y.Y. Zou, G. Kroog, and K.K. Iwata Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines Clin. Cancer Res. 11 2005 1572 1578 (Pubitemid 40315242)
20. H.K. Dressman, A. Berchuck, G. Chan, J. Zhai, A. Bild, and R. Sayer An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer J. Clin. Oncol. 25 2007 517 525 (Pubitemid 350002958)
21. R.S. Fehrmann, X.Y. Li, A.G. van der Zee, S. de Jong, G.J. te Meerman, and E.G. de Vries Profiling studies in ovarian cancer: a review Oncologist 12 2007 960 966 (Pubitemid 47359138)
22. E. Felip, F. Rojo, M. Reck, A. Heller, B. Klughammer, and G. Sala A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy Clin. Cancer Res. 14 2008 3867 3874
23. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int. J. Cancer 127 2010 2893 2917
24. T. Fojo, and D.R. Parkinson Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin. Cancer Res. 16 2010 5972 5980
25. M. Friedlander, K.C. Hancock, D. Rischin, M.J. Messing, C.A. Stringer, and G.M. Matthys A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer Gynecol. Oncol. 119 2010 32 37
26. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, and J.Y. Douillard Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) J. Clin. Oncol. 21 2003 2237 2246 (Pubitemid 46621858)
27. N. Fujimoto, K. Kiura, N. Takigawa, Y. Fujiwara, S. Toyooka, and S. Umemura Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer Acta Med. Okayama 64 2010 33 37
28. S.M. Gadgeel, J.C. Ruckdeschel, E.I. Heath, L.K. Heilbrun, R. Venkatramanamoorthy, and A. Wozniak Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC) J. Thorac. Oncol. 2 2007 299 305 (Pubitemid 47181712)
29. S.M. Gadgeel, M.L. Cote, A.G. Schwartz, L.H. Matherly, A. Wozniak, and G. Bepler Parameters for individualizing systemic therapy in non-small cell lung cancer Drug Resist. Updat. 13 2010 196 204
30. M. Galetti, R.R. Alfieri, A. Cavazzoni, M.S. La, M. Bonelli, and C. Fumarola Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines Biochem. Pharmacol. 80 2010 179 187
31. A.F. Gazdar, H. Shigematsu, J. Herz, and J.D. Minna Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol. Med. 10 2004 481 486 (Pubitemid 39303620)
32. D.E. Gerber, and J.D. Minna ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time Cancer Cell 18 2010 548 551
33. P. Giménez-Bonafé, A. Tortosa, and R. Pérez- Tomás Overcoming drug resistance by enhancing apoptosis of tumor cells Curr. Cancer Drug Targets 9 2009 320 340
34. J. Goffin, C. Lacchetti, P.M. Ellis, Y.C. Ung, and W.K. Evans First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review J. Thorac. Oncol. 5 2010 260 274
35. A.N. Gordon, N. Finkler, R.P. Edwards, A.A. Garcia, M. Crozier, and D.H. Irwin Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study Int. J. Gynecol. Cancer 15 2005 785 792 (Pubitemid 41783082)
36. R.S. Herbst, V.J. O'Neill, L. Fehrenbacher, C.P. Belani, P.D. Bonomi, and L. Hart Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer J. Clin. Oncol. 25 2007 4743 4750 (Pubitemid 350086476)
37. Y. Hiraishi, T. Wada, K. Nakatani, I. Tojyo, T. Matsumoto, and N. Kiga EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines Pathol. Oncol. Res. 14 2008 39 43
38. F.R. Hirsch, M. Varella-Garcia, P.A. Bunn Jr., M.V. Di Maria, R. Veve, R.M. Bremmes, A.E. Barón, C. Zeng, and W.A. Franklin Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J. Clin. Oncol. 21 2003 3798 3807 (Pubitemid 46606235)
39. H. Hirte, A. Oza, K. Swenerton, S.L. Ellard, R. Grimshaw, and B. Fisher A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149) Gynecol. Oncol. 118 2010 308 312
40. H.W. Hirte, L. Vidal, G.F. Fleming, A.K. Sugimoto, R.J. Morgan, and J.J. Biagi A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial ASCO Meet. Abstr. 26 2008 5521
41. S.S. Hsieh, C. Malerczyk, A. Aigner, and F. Czubayko ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation Int. J. Cancer 86 2000 644 651 (Pubitemid 30249874)
42. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat. Rev. Cancer 5 2005 341 354 (Pubitemid 40637826)
43. F. Jacob, D.R. Goldstein, D. Fink, and V. Heinzelmann-Schwarz Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs Biomark. Med. 3 2009 743 756
44. M.L. Janmaat, F.A. Kruyt, J.A. Rodriguez, and G. Giaccone Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clin. Cancer Res. 9 2003 2316 2326 (Pubitemid 36687658)
45. H. Ji, X. Zhao, Y. Yuza, T. Shimamura, D. Li, and A. Protopopov Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors Proc. Natl. Acad. Sci. U.S.A. 103 2006 7817 7822
46. H. Kawai, K. Kiura, M. Tabata, T. Yoshino, I. Takata, and A. Hiraki Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy Lung Cancer 35 2002 305 314 (Pubitemid 34158665)
47. E.S. Kim, V. Hirsh, T. Mok, M.A. Socinski, R. Gervais, and Y.L. Wu Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
48. W. Kolch, and A. Pitt Functional proteomics to dissect tyrosine kinase signalling pathways in cancer Nat. Rev. Cancer 10 2010 618 629
49. T. Kosaka, Y. Yatabe, H. Endoh, K. Yoshida, T. Hida, and M. Tsuboi Analysis of epidermal growth factor receptor gene mutation in patients with non-small-cell lung cancer and acquired resistance to gefitinib Clin. Cancer Res. 12 2006 5764 5769 (Pubitemid 44629607)
50. M.G. Kris, R.B. Natale, R.S. Herbst, J. Lynch, D. Prager, and C.P. Belani Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial J. Am. Med. Assoc. 290 2003 2149 2158 (Pubitemid 37432975)
51. K. Kubota, Y. Nishiwaki, T. Tamura, K. Nakagawa, K. Matsui, and K. Watanabe Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study J. Thorac. Oncol. 3 2008 1439 1445
52. H. Kuroda, T. Sugimoto, K. Ueda, S. Tsuchida, Y. Horii, and J. Inazawa Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy Int. J. Cancer 47 1991 732 737
53. L. Lacroix, P. Pautier, P. Duvillard, N. Motte, P. Saulnier, and J.M. Bidart Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations Int. J. Cancer 118 2006 1068 1069 (Pubitemid 43157690)
54. J.M. Lafky, J.A. Wilken, A.T. Baron, and N.J. Maihle Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer Biochim. Biophys. Acta (Rev. Cancer) 1785 2008 232 265
55. H. Lassus, H. Sihto, A. Leminen, H. Joensuu, J. Isola, and N.N. Nupponen Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma J. Mol. Med. 84 2006 671 681 (Pubitemid 44164262)
56. D.H. Lee, K. Park, J.H. Kim, J.S. Lee, S.W. Shin, and J.H. Kang Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy Clin. Cancer Res. 16 2010 1307 1314
57. J.W. Lee, Y.H. Soung, S.Y. Kim, W.S. Park, S.W. Nam, and J.Y. Lee Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer Int. J. Cancer 113 2005 510 511 (Pubitemid 40038725)
58. S. Lee, E.J. Choi, C. Jin, and D.H. Kim Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line Gynecol. Oncol. 97 2005 26 34 (Pubitemid 40403670)
59. R. Lilenbaum, R. Axelrod, S. Thomas, A. Dowlati, L. Seigel, and D. Albert Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 J. Clin. Oncol. 26 2008 863 869 (Pubitemid 351398077)
60. V.L. Locke, R.A. Davey, and M.W. Davey Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells Br. J. Haematol. 106 1999 86 91 (Pubitemid 29343531)
61. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib New Engl. J. Med. 350 2004 2129 2139 (Pubitemid 38637993)
62. C. Mao, L.-X. Qiu, R.-Y. Liao, F.-B. Du, H. Ding, and W.-C. Yang KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies Lung Cancer 69 2010 272 278
63. M. Markman, and W. Hoskins Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population J. Clin. Oncol. 10 1992 513 514
64. R. Maruyama, Y. Nishiwaki, T. Tamura, N. Yamamoto, M. Tsuboi, and K. Nakagawa Phase III study V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer J. Clin. Oncol. 26 2008 4244 4252
65. U.A. Matulonis, S. Berlin, P. Ivy, K. Tyburski, C. Krasner, and C. Zarwan Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer J. Clin. Oncol. 27 2009 5601 5606
66. E.C. Merkhofer, P. Cogswell, and A.S. Baldwin Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha Oncogene 29 2010 1238 1248
67. M. Michaelis, J. Bliss, S.C. Arnold, N. Hinsch, F. Rothweiler, and H.E. Deubzer Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins Clin. Cancer Res. 14 2008 6531 6537
68. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, and N. Saijo Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma New Engl. J. Med. 361 2009 947 957
69. A. Morabito, M.C. Piccirillo, F. Falasconi, G. De Feo, A. Del Giudice, and J. Bryce Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions Oncologist 14 2009 378 390
70. F. Morgillo, E. D'Aiuto, T. Troiani, E. Martinelli, T. Cascone, and R. De Palma Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors Lung Cancer 2010 10.1016/j.lungcan.2010.06.005
71. H. Nagahara, K. Mimori, M. Ohta, T. Utsunomiya, H. Inoue, G.F. Barnard, M. Ohira, K. Hirakawa, and M. Mori Somatic mutations of epidermal growth factor receptor in colorectal carcinoma Clinical Cancer Research 11 4 2005 1368 1371 (Pubitemid 40315215)
72. R.B. Natale, D. Bodkin, R. Govindan, B.G. Sleckman, N.A. Rizvi, and A. Capo Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study J. Clin. Oncol. 27 2009 2523 2529
73. R.B. Natale, S. Thongprasert, F.A. Greco, M. Thomas, C.M. Tsai, and P. Sunpaweravong Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST) J. Clin. Oncol. 27 15 Suppl. 2009 8009 (Meeting Abstracts)
74. S. Novello, G.V. Scagliotti, R. Rosell, M.A. Socinski, J. Brahmer, and J. Atkins Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer Br. J. Cancer 101 2009 1543 1548
75. K.J. O'Byrne, S. Danson, D. Dunlop, N. Botwood, F. Taguchi, and D. Carbone Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer J. Clin. Oncol. 25 2007 3266 3273 (Pubitemid 47325611)
76. M. Ono, A. Hirata, T. Kometani, M. Miyagawa, S.i. Ueda, and H. Kinoshita Sensitivity to gefitinib (Iressa ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation Mol. Cancer Ther. 3 2004 465 472 (Pubitemid 39193724)
77. P. Pautier, F. Joly, P. Kerbrat, P. Bougnoux, P. Fumoleau, and T. Petit Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074) Gynecol. Oncol. 116 2010 157 162
78. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
79. R. Perez-Soler, A. Chachoua, L.A. Hammond, E.K. Rowinsky, M. Huberman, and D. Karp Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J. Clin. Oncol. 22 2004 3238 3247 (Pubitemid 41103678)
80. G. Ping, W. Hui-Min, W. Wei-Min, and H. Bao-Hui Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population Med. Oncol. 2010 10.1007/s12032-010-9500-9
81. E.M. Posadas, M.S. Liel, V. Kwitkowski, L. Minasian, A.K. Godwin, and M.M. Hussain A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer Cancer 109 2007 1323 1330 (Pubitemid 46466559)
82. A. Psyrri, M. Kassar, Z. Yu, A. Bamias, P.M. Weinberger, and S. Markakis Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer Clin. Cancer Res. 11 2005 8637 8643 (Pubitemid 43005911)
83. A. Rajeswaran, A. Trojan, B. Burnand, and M. Giannelli Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials Lung Cancer 59 2008 1 11
84. S. Ramalingam, J. Forster, C. Naret, T. Evans, M. Sulecki, and H. Lu Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study J. Thorac. Oncol. 3 2008 258 264 (Pubitemid 351654325)
85. M. Ranson, M. Reck, A. Anthoney, A.R. Hanauske, E. Dean, and I. Melezinek Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study Ann. Oncol. 21 2010 2233 2239
86. L.A.G. Ries, J.L. Young, G.E. Keel, M.P. Eisner, Y.D. Lin, and M.-J. Horner SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics 2007 National Cancer Institute, SEER Program, NIH Pub. No. 07-6215 Bethesda, MD
87. P.J. Roberts, T.E. Stinchcombe, C.J. Der, and M.A. Socinski Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J. Clin. Oncol. 28 2010 4769 4777
88. D.D. Rosa, G. Ismael, L.D. Lago, and A. Awada Molecular-targeted therapies: lessons from years of clinical development Cancer Treat. Rev. 34 2008 61 80 (Pubitemid 351168606)
89. D.H. Roukos Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care Expert Rev. Mol. Diagn. 10 2010 33 48
90. V. Rusch, J. Baselga, C. Cordon-Cardo, J. Orazem, M. Zaman, and S. Hoda Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung Cancer Res. 53 1993 2379 2385 (Pubitemid 23156828)
91. A. Santoro, R. Cavina, F. Latteri, P.A. Zucali, V. Ginanni, and E. Campagnoli Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer Ann. Oncol. 15 2004 33 37 (Pubitemid 38139600)
92. R.J. Schilder, M.W. Sill, X. Chen, K.M. Darcy, S.L. Decesare, and G. Lewandowski Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study Clin. Cancer Res. 11 2005 5539 5548 (Pubitemid 41060831)
93. S. Schubbert, K. Shannon, and G. Bollag Hyperactive Ras in developmental disorders and cancer Nat. Rev. Cancer 7 2007 295 308 (Pubitemid 46480970)
94. T. Servidei, A. Riccardi, S. Mozzetti, C. Ferlini, and R. Riccardi Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib Int. J. Cancer 123 2008 2939 2949
95. T. Servidei, A. Riccardi, M. Sanguinetti, C. Dominici, and R. Riccardi Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation J. Cell. Physiol. 208 2006 220 228 (Pubitemid 43849008)
96. T. Servidei, C. Ferlini, A. Riccardi, D. Meco, and G. Scambia The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin Eur. J. Cancer 37 2001 930 938 (Pubitemid 32323973)
97. M.M. Shahzad, G. Lopez-Berestein, and A.K. Sood Novel strategies for reversing platinum resistance Drug Resist. Updat. 12 2009 148 152
98. S.V. Sharma, D.W. Bell, J. Settleman, and D.A. Haber Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer 7 2007 169 181
99. Q.B. She, D. Solit, A. Basso, and M.M. Moasser Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling Clin. Cancer Res. 9 2003 4340 4346 (Pubitemid 37248389)
100. F.A. Shepherd, P.J. Rodrigues, T. Ciuleanu, E.H. Tan, V. Hirsh, and S. Thongprasert Erlotinib in previously treated non-small-cell lung cancer New Engl. J. Med. 353 2005 123 132 (Pubitemid 41058344)
101. M.A. Socinski, S. Novello, J.R. Brahmer, R. Rosell, J.M. Sanchez, and C.P. Belani Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer J. Clin. Oncol. 26 2008 650 656 (Pubitemid 351264362)
102. S. Stadlmann, U. Gueth, U. Reiser, P.A. Diener, A.G. Zeimet, and E. Wight Epithelial growth factor receptor status in primary and recurrent ovarian cancer Mod. Pathol. 19 2006 607 610
103. K.D. Steffensen, M. Waldstrom, D.A. Olsen, T. Corydon, K.A. Lorentzen, and H.J. Knudsen Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors Clin. Cancer Res. 14 2008 3278 3282
104. B.K. Stordal, M.W. Davey, and R.A. Davey Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells Cancer Chemother. Pharmacol. 58 2006 256 265
105. B. Stordal, and M. Davey Understanding cisplatin resistance using cellular models IUBMB Life 59 2007 696 699 (Pubitemid 350035586)
106. B. Stordal, N. Pavlakis, and R. Davey A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship Cancer Treat. Rev. 33 2007 688 703 (Pubitemid 350089290)
107. B. Stordal, N. Pavlakis, and R. Davey Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review Cancer Treat. Rev. 33 2007 347 357 (Pubitemid 46760527)
108. T. Suzuki, T. Nakagawa, H. Endo, T. Mitsudomi, A. Masuda, and Y. Yatabe The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status Lung Cancer 42 2003 35 41 (Pubitemid 37153133)
109. Y. Tanaka, Y. Terai, A. Tanabe, H. Sasaki, T. Sekijima, and S. Fujiwara Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer Cancer Biol. Ther. 11 2011 50 57
110. L.R. Triano, H. Deshpande, and S.N. Gettinger Management of patients with advanced non-small cell lung cancer: current and emerging options Drugs 70 2010 167 179
111. P.A. Vasey, J. Herrstedt, and S. Jelic ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma Ann. Oncol. 16 Suppl. 1 2005 i13 i15
112. J. Vermeij, E. Teugels, C. Bourgain, J. Xiangming, P. in't Veld, and V. Ghislain Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers BMC Cancer 8 2008 3
113. U. Wagner, A. du Bois, J. Pfisterer, J. Huober, S. Loibl, and H.-J. Lück Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy - a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6) Gynecol. Oncol. 105 2007 132 137 (Pubitemid 46441449)
114. Z. Wang, Y.L. Wu, G.C. Zhang, Q. Zhou, C.R. Xu, and A.L. Guo EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients Onkologie 31 2008 174 178 (Pubitemid 351700540)
115. M.A. Westhoff, and S. Fulda Adhesion-mediated apoptosis resistance in cancer Drug Resist. Updat. 12 2009 127 136
116. I.B. Weinstein, and A. Joe Oncogene addiction Cancer Res. 68 2008 3077 3088
117. C. Yamamoto, Y. Basaki, A. Kawahara, K. Nakashima, M. Kage, and H. Izumi Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations Cancer Res. 70 2010 8715 8725
118. P. Yang, M.S. Allen, M.C. Aubry, J.A. Wampfler, R.S. Marks, and E.S. Edell Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003 Chest 128 2005 452 462 (Pubitemid 40994510)
119. X. Yang, M. Fraser, U.M. Moll, A. Basak, and B.K. Tsang Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway Cancer Res. 66 2006 3126 3136
120. C.H. Yun, K.E. Mengwasser, A.V. Toms, M.S. Woo, H. Greulich, and K.K. Wong The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U.S.A. 105 2008 2070 2075 (Pubitemid 351439466)
121. X.T. Zhang, L.Y. Li, X.L. Mu, Q.C. Cui, X.Y. Chang, and W. Song The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer Ann. Oncol. 16 2005 1334 1342 (Pubitemid 41158479)